Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05032625 Terminated - Clinical trials for Necrotizing Soft Tissue Infection

To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections

Start date: July 1, 2019
Phase:
Study type: Observational

There is significant mortality associated with necrotizing soft tissue infections, it is imperative to decrease mortality and complications associated with this disease is determined. To accomplish this goal, study team will create a prospectively maintained database of all NSTI patients admitted at department of surgery. Investigators will asses the predictors of poor outcome and follow these patients for 1 year in clinic and asses the functional quality of life by incorporating 36-Item Short Form Survey (SF-36) score.

NCT ID: NCT04912180 Terminated - Influenza Clinical Trials

Apple Respiratory Study

ARS
Start date: April 6, 2021
Phase:
Study type: Observational

The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective, longitudinal cohort, low risk Study to collect certain data from Apple Watch and iPhone to determine whether such data can detect physiologic and non-physiologic changes in individuals associated with respiratory illnesses due to influenza, SARS-CoV-2 and other respiratory pathogens (the "Study").

NCT ID: NCT04815018 Terminated - Clinical trials for SARS-CoV-2 Infection

Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

COVID-19
Start date: October 7, 2020
Phase:
Study type: Observational

This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.

NCT ID: NCT04725097 Terminated - Covid19 Clinical Trials

A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection

Start date: December 10, 2020
Phase:
Study type: Observational

The purpose of this study is to assess the ability of an artificial intelligence smartphone-enabled point of care ECG to detect COVID-19.

NCT ID: NCT04648696 Terminated - Infection Clinical Trials

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

Start date: March 3, 2021
Phase: Phase 4
Study type: Interventional

Evaluate the safety and outcomes associated between the two treatment modalities

NCT ID: NCT04610489 Terminated - Covid-19 Clinical Trials

Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)

Start date: November 13, 2020
Phase: N/A
Study type: Interventional

A comparison of a direct antigen test for SARS-CoV-2 obtained by mid-turbinate swab with the reference standard rt-PCR test obtained by nasopharyngeal swab in outpatients with symptoms compatible with COVID-19.

NCT ID: NCT04422691 Terminated - COVID-19 Clinical Trials

Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection

COVIDUS-NOR
Start date: July 1, 2020
Phase:
Study type: Observational

In light of the ongoing COVID-19 epidemic in Norway, it is paramount to develop and utilize clinical tools for assessing and risk stratifying patients with suspected coronary infection in the emergency departments. Diagnostic use of ultrasound in viral pneumonias, including COVID-19 has proved to be very useful. The use of ultrasound will assist in quick detection of lung pathology compatible with increasing severity of the COVID-19 disease. At the same time, the use of ultrasound diagnostics in the emergency department could improve logistics and reduce potential exposure of the corona virus to other health personnel. The purpose of the study is to assess whether ultrasound findings correlates with physical examination, labs, and other imaging diagnostics in patients with suspected or diagnosed COVID-19 disease, as well as assessing whether ultrasound diagnostics can assist in risk stratification. The project is conducted as a prospective multicenter study where ultrasound diagnostics will be performed on patients with suspected coronary infection in the emergency departments. Data collection takes place as part of the daily clinical evaluation of acute patients in the emergency departments. The project is planned to be completed towards the end of 2025.

NCT ID: NCT04416399 Terminated - Clinical trials for Coronavirus Infection

STerOids in COVID-19 Study

STOIC
Start date: July 16, 2020
Phase: Phase 2
Study type: Interventional

At the time of writing (3/4/2020), close to a million people have been infected by the SARS-CoV-2 coronavirus around the world. The severe clinical condition that leads to deaths is now called CoVID-19. Currently, there are no effective treatments for the early or late stages of this illness. Governments worldwide have undertaken dramatic interventions to try and reduce the rate of spread of this deadly coronavirus. Early data from multiple studies in China, where the virus originated, show that severe cases of CoVID-19 are not as prevalent in patients with chronic lung diseases as expected. This data has been confirmed by the Italian physicians. The investigators think that the widespread use of inhaled corticosteroids reduces the risk of CoVID-19 pneumonia in patients with chronic lung disease. Early microbiological data also shows that these corticosteroids are effective at slowing down the rate of coronavirus replication on lung cells. Inhaled corticosteroids are widely used to manage common lung conditions, such as asthma. This type of medicine is among the top 3 most common medication prescribed around the world. Their safety is well understood, and their potential side effects are mild and reversible. The investigators propose to test this idea that, in participants early in the course of CoVID-19 illness, daily high dose inhaled corticosteroids for 28 days, will reduce the chances of severe respiratory illness needing hospitalisation. We will also study the effect of this inhaled therapy on symptoms and viral load.

NCT ID: NCT04408183 Terminated - Infection Clinical Trials

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Start date: June 10, 2020
Phase: Phase 2
Study type: Interventional

This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.

NCT ID: NCT04403646 Terminated - COVID-19 Clinical Trials

Tannin Specific Natural Extract for COVID-19 Infection

TanCOVID
Start date: June 12, 2020
Phase: N/A
Study type: Interventional

There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti- inflammatory, anti-oxidative effects and their modulation of the intestinal microbiota. This randomized controlled trial seeks to evaluate the efficacy of the tannins based dietary supplement ARBOX in positive COVID-19 patients.